Rigel Pharmaceuticals, Inc.
About
30.05USD+0.57 +1.93%
Closed • Updated at 08:15 GMT+00:00Market Cap$555.99M
P/E Ratio1.61
Volume299.8K
Beta1.87
RSI54.24
Gross Margin93.39%
Rigel Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 21 2026
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 12 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 5 2026
Rigel Reports First Quarter 2026 Financial Results
Apr 28 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Mar 31 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Recent Videos
Rigel Pharmaceuticals VEPPANU Licensing Agreement Conference Call | May 12, 2026
May 14, 2026
RIGL STOCK : NEXT BIG MOVE | RIGEL PHARMACEUTICALS INC STOCK
May 13, 2026
Rigel Pharmaceuticals' 2025 Financial Surge! #RIGL #BiotechInvesting #FinancialForecast
Mar 31, 2026
Rigel Pharmaceuticals Inc. 2025 annual report
Mar 05, 2026
Community Chat
Ask AI
Try asking